Three studies show the drug, Eisai’s eribulin, was effective and tolerated in patients with breast cancer, colon cancer and urinary cancer, according to brief data released on Thursday by the American Society of Clinical Oncology. Sarcomas are cancers that grow from muscle or bone.
The drug is not yet approved, but Eisai has filed with relevant agencies in Japan, the United States and Europe.
The drug works on the same principle, but with a slightly different mechanism as older cancer drugs such as the taxanes and is infused intravenously.
Researchers at Aichi Cancer Center in Nagoya, Japan and several other Japanese sites tested eribulin in 81 breast cancer patients whose cancer had come back despite several rounds of chemotherapy.
Read the rest of the story: Sea sponge-derived drug treats several cancers